No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PBH Prestige Consumer Healthcare
- 68.030
- -0.030-0.04%
Close Apr 17 16:00 ET
3.38BMarket Cap-42518P/E (TTM)
68.545High67.449Low171.41KVolume68.370Open68.060Pre Close11.65MTurnover0.35%Turnover RatioLossP/E (Static)49.65MShares75.31052wk High2.11P/B3.35BFloat Cap55.96052wk Low--Dividend TTM49.30MShs Float75.310Historical High--Div YieldTTM1.61%Amplitude3.920Historical Low67.946Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Fanatics Aims for Explosive Growth After Completing Acquisition of PointsBet U.S.
Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well o
Here's Why Prestige Consumer Healthcare (PBH) Is a Strong Momentum Stock
Is Prestige Consumer Healthcare Inc. (NYSE:PBH) Trading At A 49% Discount?
Prestige Consumer HC, Rush Street Interactive, and Zeta - Added to Oppenheimer's Trifecta List
Small-caps Continue to Stay Safe as They Have Not Hit 20% Below 200-day MA - Oppenheimer
Comments
Investors seem to focus more on the company's revenue growth despite the decrease in earnings per share. The company's long-term track record of an annual TSR of 20% over five years makes it a business worth watching.
Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144% 1
Investors may be expecting a turnaround in the company's lackluster revenue performance, hence the moderate P/S ratio. However, the company's muted revenue growth estimates compared to the industry make its current P/S ratio unexpected. A positive change is needed to justify this ratio.
1
Prestige Consumer Healthcare's revenue growth is predicted to slow, with an estimated annual growth rate of 1.9% until 2025, significantly below the historical 4.2% p.a. growth. Compared to industry peers forecasted to grow at 9.0% per year, Prestige is expected to lag behind.
An insider selling shares below the current price may suggest they deemed the lower price fair, questioning their view of the recent higher valuation. However, this is a weak sign as it doesn't imply insiders think the shares are fully valued. The level of insider ownership indicates a reasonable alignment with shareholder interests.
ColumnsToday's pre-market stock movers: PTON, NVAX, AMC, SONY and more
Gainers:
• $Biohaven(BHVN.US$ +70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven)
• $Vroom(VRM.US$ +33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO)
• $Nuvve(NVVE.US$ +10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets)
• $ShockWave Medical(SWAV.US$ +14.6% (I...
• $Biohaven(BHVN.US$ +70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven)
• $Vroom(VRM.US$ +33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO)
• $Nuvve(NVVE.US$ +10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets)
• $ShockWave Medical(SWAV.US$ +14.6% (I...
20
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg